RxDoctor Payments Data

Courtney Arn

Women's Health · Franklin, OHNPI 1669996815

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Genmab U.S., Inc. at 33.1% of the total. Among women's health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$195,169in general payments, 2019–2025

Across 325 payments — averaging $600.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genmab U.S., Inc.$65K
  • Eisai Inc.$46K
  • AbbVie$24K
  • Pfizer$16K
  • Seagen Inc.$14K
  • Immunogen, Inc.$11K
  • plus $18K from 4 others

What the payments were for

  • Consulting fees$31,62616%
  • Speaking & faculty fees$106,14354%
  • Travel & lodging$49,37225%
  • Food & beverage$8,0284%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genmab U.S., Inc.107$64,614
Eisai Inc.61$46,446
AbbVie56$24,423
Pfizer33$16,179
Seagen Inc.25$13,747
Immunogen, Inc.23$11,478
AstraZeneca7$9,151
GSK7$5,013
Corcept Therapeutics5$2,318
Roche Diagnostics Corporation1$1,800

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195,169 in reported general payments places this provider in the 95th percentile of 333 women's health providers in Ohio.

See all women's health providers in Ohio

Medicare billing

Part B allowed, 2024
$14,345
Medicare patients
100
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$38,839
XareltoRivaroxaban34$25,908
Duloxetine Hcl76$1,320
Gabapentin104$1,138
Letrozole35$1,080
Dexamethasone43$920
Dexamethasone Sodium Phosphate20$849
Megestrol Acetate23$603
Ondansetron OdtOndansetron22$491
Oxycodone Hcl57$467
Nystatin26$440
Pregabalin21$424
Bupropion XlBupropion Hcl19$375
Famotidine33$331
Prochlorperazine Maleate32$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16,179$38,83960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 333 women's health providers in Ohio.

Other women's health in Franklin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →